A Phase IIb, Open-label, Randomized Study of Nab-Paclitaxel and Gemcitabine plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer (VIRAGE)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511290-30-00

Acronym

P-VCNA-003

Enrollment

Registered

2024-10-02

Start date

2022-11-15

Completion date

2025-03-28

Last updated

2024-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Pancreatic Cancer

Brief summary

OS, Safety and tolerability

Detailed description

PFS or TTP, ORR, DCR (SD + PR + CR), Landmark 1-year survival and PFS at the 1-year landmark, DoR, Changes in tumor marker Ca 19.9

Interventions

DRUGVCN-01

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
OS, Safety and tolerability	—

Secondary

Measure	Time frame
PFS or TTP, ORR, DCR (SD + PR + CR), Landmark 1-year survival and PFS at the 1-year landmark, DoR, Changes in tumor marker Ca 19.9	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026